Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of baricitinib in systemic lupus erythematosus
NL-OMON49425Phase 3Active, not recruiting
- Sponsor
- PPD
- Start
- Feb 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in systemic lupus erythematosus (SLE) (4 arms), sponsored by PPD. Primary endpoint: Long-term safety and tolerability. Started Feb 2021; status: active, not recruiting.
02
Drugs
baricitinib
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NL-OMON49425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49425.